Skip to main content

08-10-2018 | Image

New Content Item

Table 4. Endocrine IRAEs with PD1–CTLA4 combination therapy

CTLA4, cytotoxic T-lymphocyte antigen 4; IRAEs, immune-related adverse events; NR, not reported; PD1, programmed cell death protein 1.

*Includes autoimmune thyroiditis, unspecified thyroid disorders.

‡Only concurrent combo therapy reported. Sequenced treatment arm (n = 33) was not reported.

§Unspecified cause.

||Percentage determined by total number of events divided from total number of patients only from studies reporting event.

Image Credits